CliffBio
small molecule

MEZOFY

ARIPIPRAZOLE

Loss of exclusivityAugust 2033latest FDA-listed patent expiry
CompanyCMG Pharmaceutical →See this company's full patent-cliff portfolio

Drug detail

Brand nameMEZOFY
Active ingredientARIPIPRAZOLE
Strength5MG
Dosage formFILM
RouteORAL
ModalitySmall molecule
FDA approvalApril 2025
Marketing statusDISCN

Listed patents

PatentExpiresType
9694008August 2033product

More from CMG Pharmaceutical

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

MEZOFY patent cliff — loss of exclusivity August 2033 | CliffBio